anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Consumption of high-fat diets (HFDs) is a contributing factor to obesity, insulin resistance and non-alcoholic fatty liver disease (NAFLD). Several studies suggested the protective role of bioactives present in Citrus fruits against the above mentioned chronic metabolic conditions. In this study, we evaluated if a flavonoid-rich extract of Citrus bergamia (bergamot) juice (BJe) could inhibit HFD-induced intestinal permeability and endotoxemia and, through this mechanism, mitigate the associated hepatic damage in C57BL/6J mice. After 12 weeks of the treatment, HFD consumption caused high body weight (BW) gain, hyperinsulinemia, hyperglycemia, and dyslipidemia, which were mitigated by BJe (50 mg per kg BW) supplementation. Furthermore, supplementation with BJe prevented HFD-induced liver alterations, including increased plasma alanine aminotransferase (ALT) activity, increased hepatic lipid deposition, high NAS, and fibrosis. Mice fed a HFD for 12 weeks showed (i) a decrease in small intestine tight junction protein levels (ZO-1, occludin, and claudin-1), (ii) increased intestinal permeability, and (iii) endotoxemia. All these adverse events were mitigated by BJe supplementation. Linking the capacity of BJe to prevent HFD-associated endotoxemia, supplementation with this extract decreased the HFD-induced overexpression of hepatic TLR-4, downstream signaling pathways (MyD88, NF-κB and MAPK), and the associated inflammation, evidenced by increased MCP-1, TNF-α, IL-6, iNOS, and F4/80 levels. Overall, we suggest that BJe could mitigate the harmful consequences of western style diet consumption on liver physiology by protecting the gastrointestinal tract from permeabilization and associated metabolic endotoxemia.
Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician.
All patients who are considered candidates for spinal cord stimulator implant will be assigned to the "Treatment Group". Participiants will be clinically evaluated and given the Owenstry low back disability index, WHODAS 12, Beck depression index and SF-36.
The demographic information of the participants (gender, age, height, body weight, body mass index, occupation, dominant extremity, education level, marital status) will be questioned with the Demographic Data Form to be created by the researchers. Except for the demographic data form, the breath-holding capacity of the participants will be evaluated by measuring the breath-holding times, and the thoracic cage mobility will be evaluated by measuring the chest circumference during normal respiration, maximal inspiration and maximal expiration. The curvature of the spine, the presence of kyphosis and lordosis will be measured using the Spinal Mouse (IDIAG m360) device, which is an objective measurement method. The flexibility of the spine and indirectly the mobility of the rib cage will be checked with the sit and lie test. The results of the evaluations will be recorded.
A hair-applicable composition and method for visually identifying a single child amongst other children engaging in water-related activities or in another public setting. The composition includes a hair-application base and a waterproof hair dye. The hair-application base is the medium by which the waterproof hair dye is applied to the hair of a child. The waterproof hair dye includes a visually-vibrant pigmenting agent and a hydrophobic enabling agent. The visually-vibrant pigmenting agent alters the hair color of the child in order to allow a supervisor to easily identify him or her. The hydrophobic enabling agent ensures the color does not wash out with water when the child is engaging in water-related activities. The waterproof hair dye is homogeneously mixed into the topical base to create a latherable homogeneous composition.
Participants will receive a single dose of PF-07976016 in up to 3 study periods. In sequence 1, participants will receive formulation A followed by formulation B. There will be 7 days between each dose as a wash out period.
PURPOSE:A safely usable antimutagenic agent, containing a specific monophenolic compound as an active ingredient and having high antimutagenic effect and very low toxicity to normal cells. CONSTITUTION:An antimutagenic agent containing a compound expressed by the formula (R is H or CH3) as an active ingredient. The dose thereof is preferably 0.1-10mg/kg/day. The compound expressed by the formula has high antimutagenic activity. The mechanism of action thereof is believed to increase the activity of an enzyme capable of repairing damage of a DNA suffered from a mutagen, exhibit the reparative effect on the DNA in the establishing process of the mutagenicity and relate to the inhibition of the development of carcinogenicity. Therefore, the agent can be safely used for the purpose of producing preventive effect on a suspicious case of mutagenicity for a long period.
Fat tissue is far more than just a place where humans store body fat. Fat tissue contains many different types of cells, such as immune cells, endothelial cells, and fat precursor cells. Differences or changes in the number of immune cells, endothelial cells, and fat precursor cells in fat tissue can have a great impact on metabolic health. The abundance of all immune cells, endothelial cells, and fat precursor cell types are known to change when a person loses or gains weight. For example, the abundance of inflammatory cells is often found to decrease markedly with weight loss - and this change has been linked to the profound improvements in metabolic health that occur with weight loss. In contrast, the effects of exercise on immune cells, endothelial cells, and fat precursor cells in fat tissue is not known. Determining the effects of exercise on changes in the cellular composition within fat tissue will provide important information for optimizing lifestyle interventions aimed at improving metabolic health.
PURPOSE:A powdery dentifrice, prepared by mixing a crude salt with a dried powder obtained by drying a powdering plant fibers consisting of wild grass, e.g. chickweed, as a principal component in such a state as not to damage the chlorophyll with stirring, and consisting of a natural material useful for the prevention of pyorrhea or carious teeth. CONSTITUTION:Plant fibers, e.g. wild grass, preferably chickweed or comfrey, as a principal component are dried not to damage the chlorophyll and then pulverized into powder. The resultant powder as a principal component is mixed with a crude salt at a weight ratio of 4:1 with stirring, and pulverized by a suitable method, e.g. a ball mill or motor-driven mortar, to give a powdery dentifrice having a particle size of about 80-200 mesh. The resultant dentifrice exhibits improved sterilizing effect on carious teeth of the wild grass and anti-inflammatory and hemostatic effect, removes the foul breath due to the large amount of the chlorophyll and inhibits the growth of injurious germs. The crude salt contained shows the sterilizing effect and hemostatic effects synergistically and exhibits the remarkable effect on the prevention of pyorrhea and carious teeth.
<P>PROBLEM TO BE SOLVED: To provide a new peptide having excellent action for the detection, diagnosis, prevention and treatment of cancers of mammals, especially human cancers, more specifically mammary cancer, an antigen composed of the peptide, an antibody against the antigen and an agent having action to inhibit the metastasis of cancer cell of especially mammary cancer, exhibiting low side actions, and useful for the diagnosis, prevention and treatment of cancers of mammals, especially human cancers, more specifically mammary cancer.  <P>SOLUTION: The peptide is expressed by the general formula. The peptide having a straight chain or branched structure is composed of three lysine units and one glycine unit bonded with each other. The antigen is composed of the peptide. The anticancer vaccine contains the peptide.  <P>COPYRIGHT: (C)2004,JPO
BACKGROUND AND AIM: Rectal hyposensitivity (RH) is common in constipation and often coexists with functional defecatory disorder (FDD). Rectal sensory thresholds are routinely evaluated with the anorectal manometry probe; however, the gold standard for the assessment of rectal sensitivity is with a barostat, use of which is limited by time constraints and availability. A novel rapid barostat bag (RBB) may facilitate measurements of rectal sensitivity. The aim is to evaluate the relationship between RH (measured by the RBB) and FDD (defined as any minor disorder of rectoanal coordination by the London classification) in constipated patients.
METHODS: Consecutive constipated patients referred for anorectal function testing underwent anorectal manometry with the 3D-HDAM probe as well as rectal sensation testing with the RBB pump. RH was defined by volume to first sensation >30%, urge to defecate >80%, or discomfort >100% (normalized to rectal capacity).
RESULTS: Fifty-three percent of constipated patients had RH. Patients with FDD had a significantly increased volume to first sensation (134.5 mL vs 102.0, P = 0.02), urge to defecate (187.0 mL vs 149.0, P = 0.04), and rectal capacity (253.5 mL vs 209.0, P = 0.04) compared to constipated patients without FDD. There was no difference in normalized sensory thresholds (percent of rectal capacity) nor the prevalence of hyposensitivity to each sensory threshold nor overall hyposensitivity.
CONCLUSION: Patients with FDD, when measured with the RBB, have increased sensory thresholds on volumetric distension, but RH was not observed when sensory threshold volume were normalized to rectal capacity. This may reflect "secondary" RH due to altered rectal biomechanics.
Adults, adolescents, and children age 6 years and older should be dosed according to Table 1. The morning and the evening dose should be taken approximately 12 hours apart.

Information for Missed Doses:

If 6 hours or less have passed since the missed morning or evening dose, the patient should take the missed dose as soon as possible and continue on the original schedule. If more than 6 hours have passed since the missed morning or evening dose, the patient should not take the missed dose. The next scheduled dose can be taken at the usual time. More than one dose should not be taken at the same time.
Prefibrotic primary myelofibrosis (prefibrotic PMF) is a myeloproliferative neoplasm with distinct characteristics comprising histopathological and clinico-biological parameters. It is classified as a subtype of primary myelofibrosis. In clinical practice, it is essential to correctly distinguish prefibrotic PMF from essential thrombocythemia especially but also overt PMF besides other myeloid neoplasms. Risk stratification and survival outcomes for prefibrotic PMF are worse than that of ET but better than that of overt PMF. Rates of progression to overt PMF and blast phase disease are also higher for prefibrotic PMF than ET. In this review we first discuss the historical context to the evolution of prefibrotic PMF as an entity, its presenting features and diagnostic criteria. We emphasize the differences between prefibrotic PMF, ET, and overt PMF with regards to presenting features and disease outcomes including thrombohemorrhagic events and progression to fibrotic and blast phase disease. Next, we discuss the risk stratification models and contextualize these in the setting of clinical management. We share our view of personalizing treatment to address unique patient needs in the context of currently available management options. Lastly, we discuss areas of critical need in clinical research and speculate on the possibility of future disease course modifying therapies in prefibrotic PMF.
Sleep deprivation (SD), defined as an inability to get a minimum of 7 hours of regular sleep at night is a serious health problem that impacts the performance of medical professionals. This study aims to determine the impact of sleep deprivation on perceived performance among medical officers (MOs). A cross-sectional study design involved 231 MOs from six disciplines in Hospital Tuanku Ja'afar, a tertiary center in the south of Malaysia. A self-administered questionnaire was introduced in the English language. The questionnaire involved the sociodemographic characteristics; job-related factors, and the Sleep Deprivation Impact Scale (SDIS). The SDIS is a 12-question scale, rated on a 5-point Likert scale from strongly disagree to strongly agree. A higher SDIS score reflected a higher impact of sleep deprivation. A total of 206 MOs returned the completed questionnaire yielding a response rate of 89.17%. The mean age of respondents was 31.68 (±3.49) years. Most of the respondents were female, of Malay ethnicity, and married. More than three-quarters (78.64%) reported sleep deprivation. Being less effective in communication and formulating diagnosis (3 (1.01) vs 2.5 (1.15),p = 0.005); taking longer time to do things (3.44 (1.07) vs 2.8 (1.34),p = 0.001); and feeling unsafe while driving (3.56 (1.25) vs 2.93 (1.55),p = 0.006) manifested significantly higher mean among sleep-deprived respondents. In conclusion, sleep deprivation is a prevalent problem; that adversely affects crucial functioning domains that may endanger patients and healthcare providers alike. Radical countermeasures are required to ensure satisfactory sleep duration and address areas jeopardizing MO safety.
All participants will wear tinted lenses for 1 hour at a time, 5 times per day. Perception (behavior) and neural function (with functional MRI and EEG) before and after this experience will be measured. In the neural measurements, activity will be recorded while participants view stripes of many different colors both with the lenses on and off. In the perceptual measurements, participants will adjust the color of a small patch to appear neutral, neither red nor green. Behavior will be measured in a variety of conditions to test different hypotheses about the origins of the mode-switching effects. These include: 1) surrounding the patch with different colors, 2) preceding the presentation of the patch with presentation of different colors, 3) presenting the tests in a red-illuminated room, 4) presenting the tests in a completely darkened room, and 5) using a head-mount-display (virtual reality goggles) to present simulated lenses that gradually change in strength.
Indigenous people in Montana are disproportionately affected by chronic illness (CI), a legacy of settler colonialism. Existing programs addressing CI self-management are not appropriate because they are not consonant with Indigenous cultures in general and the Apsáalooke culture specifically. A research partnership between the Apsáalooke (Crow Nation) non-profit organization Messengers for Health and Montana State University co-developed, implemented, and evaluated a CI self-management program for community members. This article examines qualitative and quantitative program impacts using a pragmatic cluster randomized clinical trial design with intervention and waitlist control arms. The quantitative and qualitative data resulted in different stories on the impact of the Báa nnilah program. Neither of the quantitative hypotheses were supported with one exception. The qualitative data showed substantial positive outcomes across multiple areas. We examine why the data sets led to two very different stories, and provide study strengths and limitations, recommendations, and future directions.
The sinus lift procedure has become the most common method for maxillary bone augmentation. The most frequently observed intraoperative complication is the perforation of the Schneiderian membrane. Various treatment options have been proposed for managing these perforations, including the use of resorbable membranes, centrifugated blood products as PRF, or PRGF, suturing, and fibrin glue application. While long-term studies exist for the use of resorbable membranes to close perforations, there is limited data on the long-term outcomes of suturing or gluing the perforated sinus membrane. The aim of this retrospective study is to evaluate the long-term outcomes of suturing and/or applying fibrin glue to repair perforated sinus mucosa during sinus floor elevation procedures. Between 2005 and 2009, a total of 692 patients underwent 923 sinus lift surgeries, and Schneiderian membrane perforation occurred in 202 sinus floor elevations (21.98%) across 168 patients. The main documented causes of perforations, which ranged from 2 to 10 mm in diameter, were the presence of septa, followed by thin and adherent membranes. Of the perforations, 100 (49.5%) were treated with microsurgical suturing combined with fibrin glue, 78 (38.6%) were treated with fibrin glue alone, and 24 (11.9%) were treated exclusively with suturing. Sinus grafting was performed using autogenous bone in combination with a biomaterial, following the layering technique. All surgeries resulted in primary healing without complications, enabling all patients to undergo restoration as planned. The long term clinical and radiological evaluations of 44 randomly selected patients who followed the recall program up to 10 years post operative confirmed the effectiveness of this treatment approach.
An example of a system for programming a neurostimulator may include a storage device and a pattern generator. The storage device may store a pattern library and one or more neuronal network models. The pattern library may include fields and waveforms of neuromodulation. The one or more neuronal network models may each be configured to allow for evaluating effects of one or more fields in combination with one or more waveforms in treating one or more indications for neuromodulation. The one or more neuronal network models may include a first pain model configured to allow for optimization of neurostimulation using paresthesia, the second pain model configured to allow optimization of neurostimulation using anatomy. The pattern generator may be configured to construct and approximately optimize a spatio-temporal pattern of neurostimulation and/or its building blocks using at least one or more of the first pain model or the second pain model.
The invention discloses a Chinese medicinal preparation for treating diabetes mellitus and a preparation method thereof. The Chinese medicinal preparation is prepared from lucid ganoderma serving as a main medicine, dwarf lilyturf root and rhizoma anemarrhenae which serve as deputy medicines, and ginseng which serves as an adjuvant medicine. The preparation method for the Chinese medicinal preparation comprises the following steps of: crushing lucid ganoderma, adding water, extracting, and mixing filtrate; heating and concentrating filtrate until the filtrate becomes fluid extract; standing, centrifuging, taking precipitates, drying and then crushing into fine power for later use; breaking dwarf lilyturf root, rhizoma anemarrhenae and lily, mixing and adding water, extracting and mixing filtrate; heating and concentrating the filtrate until the filtrate becomes fluid extract; standing, centrifuging, taking precipitates, drying and crushing into fine power; and mixing fine powder uniformly to obtain the Chinese medicinal preparation. The Chinese medicinal preparation has a good curative effect, is high in cure rate, and does not contain toxic matter, or have a side effect; and through clinical use, the Chinese medicinal preparation has an obvious effect on type 2 diabetes mellitus, and is short in a treatment course and healthy. The Chinese medicinal preparation can be loaded into a capsule No.1 for use and is convenient to carry. The cure rate is 86.7 percent and the effective rate is 100 percent.
Kidney stone disease (KSD, also named renal calculi, nephrolithiasis, or urolithiasis) is a common urological disease entailing the formation of minerals and salts that form inside the urinary tract, frequently caused by diabetes, high blood pressure, hypertension, and monogenetic components in most patients. 10% of adults worldwide are affected by KSD, which continues to be highly prevalent and with increasing incidence. For the identification of novel therapeutic targets in KSD, we adopted high-throughput sequencing and mass spectrometry (MS) techniques in this study and carried out an integrative analysis of exosome proteomic data and DNA methylation data from blood samples of normal and KSD individuals. Our research delineated the profiling of exosomal proteins and DNA methylation in both healthy individuals and those afflicted with KSD, finding that the overexpressed proteins and the demethylated genes in KSD samples are associated with immune responses. The consistency of the results in proteomics and epigenetics supports the feasibility of the comprehensive strategy. Our insights into the molecular landscape of KSD pave the way for a deeper understanding of its pathogenic mechanism, providing an opportunity for more precise diagnosis and targeted treatment strategies for KSD.
The mechanisms by which immunotherapy (hyposensitization) is achieved are not completely understood. Anaphylaxis or "anaphylactic shock," and hay fever are caused by the same basic process: the production of IgE antibody, its attachment to mast cells and, on renewed contact with the same antigen explosive degranulation of the mast cells and release of mediators, which act on smooth muscle, mucous glands, and blood vessels. With massive release there is bronchospasm, vomiting, skin rashes, edema of the nose and throat, and vascular collapse, sometimes fatal, while with more localized release one or more of these symptoms predominates, depending on the site (tissue shock organ) of exposure to the antigen. 

Antigens that can trigger these reactions are known as "allergens"; they have very diverse origins but a curious similarity of molecular weight. People who suffer unduly from allergy are called "atopic"; this trait is usually inherited and has been attributed to a variety of constitutional abnormalities. 

The IgE dependent degranulation of mast cells is initiated by the bridging of pairs of cell-bound IgE by antigen and terminates rapidly. Bridging results in alteration of the cell membrane, which is associated with increased energy dependent entry of calcium, alterations in phospholipid metabolism and increase of cyclic adenosine monophosphate (cyclic AMP). 

The mast cell membrane is ruffled and possesses receptors both for the Fc portion of IgE and C3b. Receptors for anaphylatoxin (C3a and C5a), have been defined functionally. In addition to IgE antigen interaction and stimulation by anaphylatoxin, mast cells may be degranulated by non-immunological stimuli such as enzymes, ionophores, polycations, radio-contrast dyes and opiates. Atopic individuals develop their symptoms principally as a result of IgE-dependent processes; however, non- IgE mediated mechanisms for the release of mast cell mediators provide additional potential for recruitment of mediators. 

Subsequent to activation, the secretion of granules is under cyclic nucleotide regulation. Of direct relevance is the possibility that the mast cell itself, by histamine (H2) and prostaglandins (E2, D2, I2) may increase cyclic AMP and inhibit secretion. Conversely histamine (H1) could elevate cyclic GMP and PGF, 2 alpha lower cyclic AMP, augmenting the release of mediators. 18